Mesoblast Secures $125M Non-Dilutive Credit Line, Reports Strong Ryoncil Sales & Extended Cash Runway

summarizeSummary

Mesoblast reported a significant increase in Ryoncil® net revenues to $30 million, secured a new $125 million non-dilutive credit facility, and extended its cash runway to over 11 quarters, alongside positive clinical and regulatory updates for its pipeline.

check_boxKey Events

• Secures $125M Non-Dilutive Credit Line

  Mesoblast entered into a new US$125 million non-dilutive credit facility at a fixed interest rate of 8.00% per annum, with US$75 million initially drawn. This significantly reduces debt costs and enhances financial flexibility.

• Strong Ryoncil® Sales Growth

  Ryoncil® net revenues reached US$30 million for the quarter ended December 31, 2025, representing a 60% increase over the prior quarter, demonstrating robust commercial traction.

• Extended Cash Runway to 11.6 Quarters

  The company reported US$130 million in cash at quarter-end and an estimated 11.6 quarters of funding available, substantially de-risking its operational outlook.

• Positive FDA Feedback for Rexlemestrocel-L BLA

  Mesoblast received positive feedback from the FDA regarding a potential Biologics License Application (BLA) filing for rexlemestrocel-L in chronic low back pain, acknowledging efficacy and opioid reduction data.

auto_awesomeAnalysis

This quarterly report signals a significant positive shift for Mesoblast, primarily driven by securing a substantial new non-dilutive credit facility. The US$125 million credit line, with a lower fixed interest rate of 8% and a five-year interest-only period, substantially reduces the company's cost of debt and provides critical financial flexibility. This, combined with US$30 million in Ryoncil® net revenues (a 60% quarter-over-quarter increase) and an extended cash runway of 11.6 quarters, significantly de-risks the company's financial position. Furthermore, positive regulatory feedback for rexlemestrocel-L's BLA filing in chronic low back pain and the planned pivotal trial for Ryoncil® in adults underscore strong pipeline progression and future growth potential. The comprehensive positive updates across financing, commercialization, and product development are highly impactful for the investment thesis.